ARROWHEAD PHARMACEUTICALS, INC. (ARWR) — SEC Financial Statements & Analysis

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) is a pharmaceutical preparations company, incorporated in DE. ARROWHEAD PHARMACEUTICALS, INC. trades on Nasdaq as: ARWR. ARROWHEAD PHARMACEUTICALS, INC. (ARWR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04. Based on that filing, ARROWHEAD PHARMACEUTICALS, INC. carries a market cap of $11.69B, a P/E ratio of -41.22x, a P/B ratio of 25.08x, a P/S ratio of 17.46x, an enterprise value of $12.35B, and an EV/EBITDA multiple of -61.58x. On profitability, it posts a gross margin of 111.47%, an operating margin of -33.82%, a net margin of -42.34%, a Return on Equity (ROE) of -57.51%, a Return on Assets (ROA) of -16.23%, and a Return on Invested Capital (ROIC) of -28.50%. Per share, it reports EPS of $-1.98, diluted EPS of $-1.98, free cash flow per share of $-0.52, and a dividend per share of $0.56. Over the trailing year, it posted revenue growth of 16.85% year-over-year, net income growth of 78.16% year-over-year, and EPS growth of 72.77% year-over-year. On the balance sheet, it maintains a current ratio of 5.90x, a quick ratio of 5.81x, working capital of $1.39B, a debt-to-equity ratio of 3.53x, a debt ratio of 0.78, an interest coverage ratio of -2.45x, free cash flow of $-75.11M (TTM), and net debt of $667.95M. Figures sourced from SEC EDGAR.

Market Cap

$11.69B

P/E TTM

-41.22x

EPS TTM

$-1.98

P/B TTM

25.08x

ROE TTM

-57.51%

ROA TTM

-16.23%

Debt To Equity

3.53x

Free Cash Flow TTM

$-75.11M

Net Revenue TTM Growth 1Y

16.85%

Data as of 2026-06-30 · Source: SEC EDGAR